CLOSTRABIO

​ClostraBio is developing a novel probiotic called CLB101™ as a dietary supplement for various applications related to maintaining and promoting gut health. This next-generation probiotic strain is an anaerobe, a spore-former and known butyrate producer, and was found to be lacking in infants with food allergy.  In research studies, when the strain was colonized in cow's milk allergic mice, it was able to reduce an allergic response to food. 

CLB101™ fermentation has been scaled to commercial production capacity to support product launch in 2025. More information will be available in the coming months.